

Guideline Committee Meeting 4

Asthma management

Date and Time: Monday 23 November 2015, 10:00-16:00

Place: Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ

Minutes: Confirmed

Present:

GC Members

John Alexander, Chair, Consultant in Paediatric Respiratory & Paediatric Intensive Care, Royal Stoke University Hospital
Noel Baxter, General Practitioner, NHS Southwark CCG
Andrew Bush, Professor of Paediatrics & Head of Section, Royal Brompton & Harefield NHS Foundation Trust
Chris Griffiths, Principal in General Practice & Professor of Primary Care, Queen Mary University of London
Val Hudson, Patient member
Matt Masoli, Consultant Respiratory Physician, Plymouth Hospitals NHS Trust
Abigail Moore, Sp Trainee, RCP Clinical Fellow
Nicola Mundy, Patient member
Ellen Nicholson, Senior Respiratory Nurse Specialist, Homerton University Hospital Foundation Trust
Prunella Neale, Practice Nurse, Herschel Medical Centre
Stephen Scott, Consultant Respiratory Physician, Countess of Chester Hospital

NCGC

Emily Davies, Senior Research Fellow
James Gilbert, Research Fellow
Alex Haines, Senior Health Economist
Bernard Higgins, Clinical Director
Samantha Jones, Project Manager
Ben Mayer, Trainee Systematic Reviewer
Peter Rouse, Health Economist
Claire Wallnutt, Information Scientist, NCGC

NICE

Caroline Keir, Guidelines Commissioning Manager

Apologies:

Mikaela Bartlett, Document Editor/Process Assistant (notes)
Susan Frost, Lead Respiratory Nurse Specialist, Birmingham Children's Hospital
Helen Haley, Pharmacist in Child Health, Royal Stoke University Hospital

Notes

1. **Welcome, apologies and introductions**

The Chair welcomed the group to the fourth meeting of this guideline committee. Apologies were received from MB, SF and HH.

The minutes from GC3 were confirmed as a true and accurate record of the meeting.

2. **Declarations of interest**

No new declarations of interest were received for this meeting.

3. **Regulation 28 Report**

The committee discussed the Regulation 28 report and agreed that it is not within the NICE remit to act upon the content of the report; however there is an opportunity to keep the outcomes of the report in mind throughout the development process.

4. **LETR: Should initial treatment include PRN SABA and regular preventer?**

The committee discussed and made minor amendments to the LETR.

5. **Evidence review: Question 5: Intermittent vs daily ICS**

JG presented the clinical evidence for the Question 5 review. PR presented economic costing analysis for the drug treatments outlined in the clinical evidence. The GC discussed the evidence and recommendations.

6. **Question 2 evidence update**

JG presented the current NMA structure for question 2. Based on the evidence available an NMA is not feasible and multiple pairwise comparisons will be presented instead.

7. **Draft protocols**

The committee discussed and made amendments to the draft protocols.

8. **Any other business**

None.

Date, time and venue of the next meeting

GC5: Tuesday 5 January 2016, 1000-1600, Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ